Mersana Therapeutics

General Information

We are a clinical stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need. We have leveraged 20 years of industry learning in the ADC field to develop proprietary technologies that enable us to design ADCs to have improved efficacy, safety and tolerability relative to existing ADC therapies. Our most advanced platform, Dolaflexin, has been used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not currently amenable to treatment with traditional ADC-based therapies.

Employees: 68
Founded: 2012
Contact Information
Address 840 Memorial Drive, Cambridge, MA 02139, US
Phone Number (617) 498-0020
Web Address
View Prospectus: Mersana Therapeutics
Financial Information
Market Cap $339.7mil
Revenues $25.8 mil (last 12 months)
Net Income $-16.4 mil (last 12 months)
IPO Profile
Symbol MRSN
Exchange NASDAQ
Shares (millions): 5.0
Price range $15.00 - $15.00
Est. $ Volume $75.0 mil
Manager / Joint Managers J.P. Morgan/ Cowen/ Leerink Partners
CO-Managers Wedbush PacGrow
Expected To Trade: 6/28/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change